Tejas Savant

“Brent, maybe starting with you at a relatively high level, that 200-bit reduction in organic growth, can you just bridge us to that between education and government, the controlled environment, consumables, the competitive intensity you guys cited, and then a little bit of a haircut on China?”

“You know, I know in the deck you talked about the number of targets only being one variable impacting tumor-informed MRD assay performance, but how many markers do you anticipate tracking for your personalized whole genome panels at 16, like the current version of Signatera, and how did you think about that choice in…”

“So just a quick follow-up there on one of Tycho's earlier questions. Is ACS guideline inclusion a second half 25 catalyst for you still, Amir Ali? And then with that Supreme Court case looming here, I know there's offsets via, you know, ACS states and the Medicare opportunities obviously insulated from that situation.”

“Just a couple of cleanups on the guide and then i have one on on the on the legal side of things as well um so maybe adam for you um any color on on gross margin cadence to the year there's a few moving pieces here obviously you mentioned the pricing headwind and and mix and so on uh but also potentially you know some…”